Michael G Grey sold $3.5M of MIRM
director at Mirum Pharmaceuticals, Inc.. 50,000 shares at an average of $70.00, traded Nov 21, 2025, filed Nov 25, 2025.
Score components
- +15RoleDirector
- +25Trade size$3.5M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001240122-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | MOption exercise Common Stock10b5-1 | +50,000 | $2.94 | $147k | 50,000 | Nov 25, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stock10b5-1 | -50,000 | $70.00 | $3.5M | 0 | Nov 25, 2025 |
| Nov 21, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 281,176 | Nov 25, 2025 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 47Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $670k 7,287 shares | -13% | |
| 42Moderate | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $435k 4,732 shares | -36% | |
| 27Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $182k 2,000 shares | -100% | |
| 55Moderate | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.8M 40,985 shares | -17% | |
| 55Moderate | Mirum Pharmaceuticals, Inc. | Peter Radovich PRESIDENT AND COO | $1.5M 16,515 shares | -29% | |
| 45Moderate | Mirum Pharmaceuticals, Inc. | Joanne Quan CHIEF MEDICAL OFFICER | $670k 7,287 shares | -28% | |
| 27Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $204k 2,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.